Resumen
Definición
Anamnesis y examen
Principales factores de diagnóstico
- excessive worry for at least 6 months
- anxiety not confined to another mental health disorder
- anxiety not due to medication or substance
- muscle tension
- sleep disturbance
- fatigue
- restlessness
- irritability
- poor concentration
Otros factores de diagnóstico
- headache
- sweating
- dizziness
- gastrointestinal symptoms
- muscle aches
- increased heart rate
- shortness of breath
- trembling
- exaggerated startle response
- chest pain
Factores de riesgo
- family history of anxiety
- physical or emotional stress
- history of physical, sexual, or emotional trauma
- other anxiety disorder
- chronic physical health condition
- female sex
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- clinical diagnosis
Pruebas diagnósticas que deben considerarse
- thyroid function tests
- urine drug screen
- 24-hour urine for catecholamines, metanephrines, normetanephrines, and creatinine
- pulmonary function tests
- ECG
Algoritmo de tratamiento
anxiety symptoms meeting DSM-5-TR criteria
anxiety symptoms not meeting DSM-5-TR criteria
Colaboradores
Autores
Philip John Cowen, MD, FRCPsych, FMedSci
Professor of Psychopharmacology
Department of Psychiatry
University of Oxford
Oxford
UK
Divulgaciones
PJC declares that he has no competing interests.
Agradecimientos
Professor Philip John Cowen would like to gratefully acknowledge Dr Christopher Gale, Dr Richard P. Swinson, Dr Elizabeth Hoge, and Dr Phebe Tucker, previous contributors to this topic.
Divulgaciones
CG is an author of the Royal Australian and New Zealand College of Psychiatrists clinical practice guideline on social phobia, panic disorder, and generalized anxiety disorder. Otago University has commercial and research relationships with multiple pharmaceutical companies. He is an author of a number of references cited in this topic. RPS has personally received royalties for articles published in UpToDate (Wolters Kluwer) and the Compendium of Therapeutic Choices, 2nd edition (Canadian Pharmacists Association). EH is an author of a number of references cited in this topic. PT has conducted research for GlaxoSmithKline, Bristol-Myers Squibb, Wyeth Pharmaceuticals, Astra-Zeneca, Cephalon, Inc., and Ortho-McNeil. She has also consulted for Forest Pharmaceuticals and received honoraria from Pfizer, Inc. and Forest Pharmaceuticals.
Revisores por pares
Lori Davis, MD
Research Director
University of Alabama
School of Medicine Tuscaloosa Campus
College of Community Health Sciences
Tuscaloosa
AL
Divulgaciones
LD declares that she has no competing interests.
Arianna Di Florio, MD, PhD
Senior Clinical Lecturer
Division of Psychological Medicine and Clinical Neurosciences
Cardiff University
United Kingdom
Divulgaciones
ADF declares that she has no competing interests.
Elaine Lockhart, MB, BCH, BAO
Consultant in Paediatric Liaison Psychiatry
Royal Hospital for Children
Glasgow
United Kingdom
Divulgaciones
EL declares that she has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
Referencias
Artículos principales
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Bandelow B, Sher L, Bunevicius R, et al; WFSBP Task Force on Mental Disorders in Primary Care; WFSBP Task Force on Anxiety Disorders, OCD and PTSD. Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract. 2012 Jun;16(2):77-84. Resumen
Bandelow B, Sagebiel A, Belz M, et al. Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies. Br J Psychiatry. 2018 Jun;212(6):333-8.Texto completo Resumen
Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019 Feb 23;393(10173):768-77. Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Panic disorder
- Social anxiety disorder
- Obsessive-compulsive disorder
Más DiferencialesGuías de práctica clínica
- Screening and diagnosis of mental health conditions during pregnancy and postpartum
- Treatment and management of mental health conditions during pregnancy and postpartum
Más Guías de práctica clínicaFolletos para el paciente
Anxiety: what is it?
Anxiety: what are the treatment options?
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad